Sofinnova Investments’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$27.9M Buy
+112,879
New +$28.7M 1.21% 21
2025
Q2
– Sell
-176,181
Closed -$47.6M – 65
2025
Q1
$47.6M Buy
176,181
+66,024
+60% +$17M 3.11% 8
2024
Q4
$25.9M Buy
+110,157
New +$29M 1.89% 17
2024
Q3
– Sell
-147,929
Closed -$35.9M – 64
2024
Q2
$35.9M Buy
147,929
+44,893
+44% +$7.09M 1.87% 18
2024
Q1
$15.4M Buy
+103,036
New +$17.2M 0.86% 31
2023
Q2
– Sell
-448
Closed -$89.7K – 53
2023
Q1
$89.7K Sell
448
-56,000
-99% -$11.8M 0.01% 52
2022
Q4
$13.4M Buy
+56,448
New +$12M 0.8% 28
2019
Q3
– Sell
-27,792
Closed -$2.02M – 75
2019
Q2
$2.02M Sell
27,792
-78,824
-74% -$6.05M 0.19% 58
2019
Q1
$10M Buy
+106,616
New +$8.92M 0.96% 21

Other funds holding ALNY

Sofinnova Investments's ALNY Position: Q3 2026 in Review

Sofinnova Investments opened a new position in Alnylam Pharmaceuticals (ALNY) in Q3 2026: 112,879 shares worth $27.9M. The stake represents 1.21% of the portfolio and ranks #21 among its holdings. This is a return to the name: Sofinnova Investments previously reported a position in ALNY as recently as Q1 2025.

Sofinnova Investments first reported a position in ALNY in Q1 2019 and has held it in 9 quarters since. The position peaked at $47.6M in Q1 2025. 720 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

  • Sofinnova Investments held 112,879 shares of Alnylam Pharmaceuticals worth $27.9M as of Q3 2026.
  • Alnylam Pharmaceuticals was a new Sofinnova Investments position in Q3 2026.
  • Alnylam Pharmaceuticals made up 1.21% of Sofinnova Investments's portfolio in Q3 2026, its #21 holding.
  • Sofinnova Investments first reported a position in Alnylam Pharmaceuticals in Q1 2019 and has held it in 9 quarters since.
  • Sofinnova Investments's Alnylam Pharmaceuticals position peaked at $47.6M in Q1 2025.
  • 720 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on Sofinnova Investments's 13F filing for Q3 2026, filed 16 Nov 2026.